Long-term effects of intravitreal bevacizumab and aflibercept on intraocular pressure in wet age-related macular degeneration
Abstract Background To evaluate the incidence of sustained elevation of intraocular pressure (SE-IOP) associated with intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF) bevacizumab and aflibercept in patients with wet age-related macular degeneration (wAMD). Methods A re...
Main Authors: | Mikael Kähkönen, Raimo Tuuminen, Vesa Aaltonen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-08-01
|
Series: | BMC Ophthalmology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12886-021-02076-1 |
Similar Items
-
Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01) -
Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
by: Junyeop Lee, et al.
Published: (2022-03-01) -
Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
by: Agnieszka Nowosielska
Published: (2019-10-01) -
One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab
by: Mahmoud Alaa Abouhussein, et al.
Published: (2021-01-01) -
Aflibercept monotherapy or bevacizumab first for diabetic macular edema
by: Avner Hostovsky, et al.
Published: (2024-01-01)